Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure

Medientyp: E-Artikel
Titel: Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
Beteiligte: Jiménez de Ory, Santiago; Beltrán-Pavez, Carolina; Gutiérrez-López, Miguel; Santos, María Del Mar; Prieto, Luis; Sainz, Talía; Guillen, Sara; Aguilera-Alonso, David; Díez, Cristina; Bernardino, Jose Ignacio; Mellado, María José; Ramos, José Tomás; Holguín, África; Navarro, Marisa; Mellado, María José; Escosa, Luis; Hortelano, Milagros García; Sainz, Talía; Rojo, Pablo; Prieto-Tato, Luis; Epalza, Cristina; Ramos, José Tomás; Illán, Marta; Guillén, Sara; [...]
Erschienen: Oxford University Press (OUP), 2021
Erschienen in: Journal of Antimicrobial Chemotherapy
Sprache: Englisch
DOI: 10.1093/jac/dkab080
ISSN: 0305-7453; 1460-2091
Schlagwörter: Infectious Diseases ; Pharmacology (medical) ; Pharmacology ; Microbiology (medical)
Entstehung:
Anmerkungen:
Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Objectives</jats:title> <jats:p>We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We included vertically HIV-infected youths/young adults aged ≥10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA &lt;50 copies/mL), and with available PBMCs in the Spanish HIV BioBank. Genomic DNA was extracted from PBMCs and HIV-1 RT gene was amplified and sequenced for resistance testing by Stanford HIV Resistance tool.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among the 225 patients under follow-up in the study cohort, 13 (5.8%) met selection criteria, and RT sequences were recovered in 12 (92.3%) of them. All but one were Spaniards, carrying subtype B, with a median age at PBMCs sampling of 21.3 years (IQR: 15.6–23.1) with 4 years (IQR 2.1–6.5) of suppressed viral load (VL). Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression. In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma.</jats:p> </jats:sec>
Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: